scholarly journals Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT

2019 ◽  
Vol 3 (21) ◽  
pp. 3287-3296
Author(s):  
Yu Akahoshi ◽  
Hideki Nakasone ◽  
Koji Kawamura ◽  
Machiko Kusuda ◽  
Shunto Kawamura ◽  
...  
Keyword(s):  
At Risk ◽  
High Risk ◽  
Graft Versus Host Disease ◽  
Binding Protein ◽  
Liver Graft ◽  
Host Disease ◽  
Allogeneic Hsct ◽  
Graft Versus Host ◽  
Key Points ◽  
Patients At Risk

Key Points M2BPGi is increased in patients with liver graft-versus-host disease, especially in those at high risk for late NRM after allogeneic HSCT. WFA+-M2BP–positive macrophages are found in liver graft-versus-host disease, supporting these cells as a responder of this glycoprotein.

scholarly journals CD19+CD21low B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome

Blood ◽  
2013 ◽  
Vol 121 (10) ◽  
pp. 1886-1895 ◽  
Author(s):  
Zoya Kuzmina ◽  
Katharina Krenn ◽  
Ventzislav Petkov ◽  
Ulrike Körmöczi ◽  
Roman Weigl ◽  
...  
Keyword(s):  
At Risk ◽  
B Cells ◽  
B Cell ◽  
Graft Versus Host Disease ◽  
Bronchiolitis Obliterans ◽  
Bronchiolitis Obliterans Syndrome ◽  
Cell Subpopulation ◽  
Graft Versus Host ◽  
Key Points ◽  
Patients At Risk

Key Points B-cell subpopulation as biomarker for NIH-defined BOS.

scholarly journals Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality

Blood ◽  
2013 ◽  
Vol 122 (8) ◽  
pp. 1505-1509 ◽  
Author(s):  
John E. Levine ◽  
Elisabeth Huber ◽  
Suntrea T. G. Hammer ◽  
Andrew C. Harris ◽  
Joel K. Greenson ◽  
...  
Keyword(s):  
High Risk ◽  
Light Microscopy ◽  
Graft Versus Host Disease ◽  
Paneth Cell ◽  
Paneth Cells ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Numbers ◽  
Key Points ◽  
Histopathological Grading

Key Points Paneth cell numbers in the duodenum at onset of GVHD correlate with outcomes. Paneth cells are easy to identify and quantify with light microscopy and may supplement histopathological grading of GI GVHD.

scholarly journals A systematic review of transfusion-associated graft-versus-host disease

Blood ◽  
2015 ◽  
Vol 126 (3) ◽  
pp. 406-414 ◽  
Author(s):  
Ilana Kopolovic ◽  
Jackie Ostro ◽  
Hideki Tsubota ◽  
Yulia Lin ◽  
Christine M. Cserti-Gazdewich ◽  
...  
Keyword(s):  
Systematic Review ◽  
At Risk ◽  
Graft Versus Host Disease ◽  
Hla Antigens ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points ◽  
Blood Irradiation ◽  
Current Guidelines ◽  
Donor Lymphocytes

Key Points Fifty percent of TA-GVHD cases occur in patients who would not be predicted to be at risk for TA-GVHD by current guidelines for blood irradiation. Donor lymphocytes whose HLA antigens are all shared by the recipient dominate in TA-GVHD cases, particularly in immune-competent recipients.

Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease

Blood ◽  
2014 ◽  
Vol 124 (5) ◽  
pp. 812-821 ◽  
Author(s):  
J. Marius Munneke ◽  
Andreas T. Björklund ◽  
Jenny M. Mjösberg ◽  
Karin Garming-Legert ◽  
Jochem H. Bernink ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Innate Lymphoid Cells ◽  
Lymphoid Cells ◽  
Host Disease ◽  
High Frequencies ◽  
Allogeneic Hsct ◽  
Graft Versus Host ◽  
Key Points ◽  
Reduced Risk

Key Points Chemotherapy and radiotherapy deplete ILCs from the blood; ILC reconstitution after allogeneic HSCT is slow. High frequencies of activated ILCs with tissue homing potential before allogeneic HSCT are associated with reduced risk for GVHD.

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

Blood ◽  
2014 ◽  
Vol 123 (24) ◽  
pp. 3832-3842 ◽  
Author(s):  
Silvia Spoerl ◽  
Nimitha R. Mathew ◽  
Michael Bscheider ◽  
Annette Schmitt-Graeff ◽  
Sophia Chen ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points

Key Points We report that ruxolitinib reduces murine GVHD via increased Treg numbers. We demonstrate the potent activity of ruxolitinib treatment in patients with corticosteroid-refractory GVHD.

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3745-3758 ◽  
Author(s):  
Emily Blyth ◽  
Leighton Clancy ◽  
Renee Simms ◽  
Chun K. K. Ma ◽  
Jane Burgess ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Allogeneic Stem Cell Transplantation ◽  
Organ Damage ◽  
Host Disease ◽  
Graft Versus Host ◽  
Key Points

Key Points Infusion of CMV-specific T cells early posttransplant does not increase acute or chronic graft-versus-host disease. CMV-specific T cells early posttransplant reduce the need for pharmacotherapy without increased rates of CMV-related organ damage.

Sign in / Sign up

Export Citation Format

Share Document